Mendra secured $82 million in Series A financing to build a company focused on acquiring, developing and commercializing therapies for rare diseases. The round, co‑led by OrbiMed, 8VC and 5AM Ventures with participation from Lux Capital and Wing VC, will be used to assemble an initial portfolio of underdeveloped rare‑disease assets and to scale clinical programs. Mendra plans to apply AI for asset selection, patient identification and global trial enrollment, and will pursue strategic partnerships to accelerate clinical and commercial execution. Management framed the strategy as a buy‑and‑build model to shorten timelines for underserved patient populations.